REFERENCE FILE
Tesamorelin
Read the record, then work through the questions.
Reference details
Status as of
- Regulatory category
- Approved product
- Evidence category
- Randomized evidence
- Mechanism
- Stimulates growth-hormone release.
- Evidence
- A randomized trial measured visceral fat.
- Limitations
- Not for weight management.
- Safety
- Active malignancy is a contraindication.
- Formulation and route
- Specified subcutaneous formulation.
- Approval scope
- Egrifta WR addresses excess abdominal fat in adults with HIV-associated lipodystrophy.
A SECOND LOOK
A question to carry into the reading
Put time back into a statement about tesamorelin by drawing a horizontal line with a clearly named starting event. Add the period of observation described in the source and mark the point to which the statement refers. Then place your own question on the same line. If it asks about an earlier or later period, shade that extension rather than silently stretching the reported result. Check whether follow-up, measurement, and the event of interest use the same starting point. Your note should explain exactly where the source's time window ends and what further observation would answer the question beyond it.
Questions to keep beside the page
- What event starts the clock for the result being described?
- Does my question concern the same period as the reported observation?
- What additional observation would be needed to address the shaded extension?
Sources for this file
- EGRIFTA WRNLM · Checked
- Falutz trialPubMed · Checked
FROM THE REFERENCE DESK